Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and New Zealand

Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and New Zealand

MUMBAI, India, March 2, 2021 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its subsidiary, Cipla Gulf FZ LCC ("Cipla Gulf') is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.

As part of this strategic...

Read more: Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and N...

More Articles …

  1. Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg)
  2. Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug
  3. Marriott International Pilots AI Solutions to Streamline Hotel Design Process for Future Properties in Asia-Pacific
  4. LCM Partners wins two Private Debt Investor 2020 awards
  5. INEOS Styrolution's Zylar 261 used in Samsung's new range of household appliances
  6. Tezos Baking enables Sylo Smart Wallet users to earn rewards from holding XTZ
  7. Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB
  8. Nintex Workflow Cloud Helps Zoom Improve Channel Order Process
  9. K7 Computing Launches Lifetime Valid Antivirus - K7 Ultimate Security Infiniti Edition
  10. CORE to open an Australian office to assist Australian entrepreneurs looking to start a business in Hong Kong